<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>25561121</identifier>
<setSpec>1699-5198</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Riobó Serván, Pilar</dc:author>
<dc:author>Vázquez Martínez, Clotilde</dc:author>
<dc:author>Sierra Poyatos, Roberto</dc:author>
<dc:description xml:lang="en">INTRODUCTION GLP-1 analogs have been shown to be an effective treatment of type 2 diabetes mellitus (DM-2) and obesity. OBJECTIVES Evaluate the efficacy of exenatide LAR on weight loss, glycemic control, blood pressure (BP) and lipid profile, in DM-2 and obesity. MATERIAL AND METHODS Retrospective study of patients treated with exenatide LAR for 6 months. Demographic data (age, gender), anthropometric, fasting glucose, glycated hemoglobin (HbA1c), blood pressure and lipid profile were collected at baseline and at 6 months after treatment. We performed a logistic regression analysis to assess possible predictors of efficacy. RESULTS 30 patients (17 male, mean age: 61.7 ± 9.5 years old) with DM-2 of 9.7 ± 6.2 years of evolution. HbA1c was reduced by 1.3% (95%CI 1.04-1.57; p &lt;0.001), weight by 2.8 kg (95%CI 1.67-3.96, p &lt;0.001) and BMI by 1.9 kg/m2 (95%CI 1,08-2,93; p &lt;0,001). Total cholesterol decreased by 26.9 mg/dl (95%CI 9.23-38.8, p = 0.003), LDL cholesterol by 21.2 mg/dl (95% CI 7.56-34.9, p = 0.02) and triglycerides by 53.9 mg/dl (95%CI 46.4-77.1 mg/dl, p = 0.004). No statistically significant changes in blood pressure and HDL cholesterol were observed. 53.3% of patients got an HbA1c &lt;7%, 66.6% lost weight, and 43.3% simultaneously achieved both of them. Neither of the studied variables was confirmed as a predictor of treatment response. Regarding side effects, 53.3% reported gastrointestinal discomfort (nausea) and 26.6% reported subcutaneous nodules of spontaneous resolution. CONCLUSIONS Treatment with exenatide LA, in obesity and DM-2, has shown beneficial effect on lipid weight, BMI, glycemic control and lipid profile, despite the long duration of diabetes in our patients.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:date>2014 Oct 24 </dc:date>
<dc:title xml:lang="es">Efectos de exenatide lar en diabetes mellitus tipo 2 y obesidad.</dc:title>
<dc:description xml:lang="es">
             Introducción: Los análogos GLP-1 han demostrado ser un tratamiento eficaz en el tratamiento de la diabetes mellitus tipo 2 (DM-2) y la obesidad. Objetivo: Evaluar la eficacia de exenatide LAR sobre la pérdida de peso, control glucémico, tensión arterial (TA) y perfil lipídico, en DM-2 y obesidad. Material y métodos: Estudio retrospectivo de pacientes en tratamiento con exenatide LAR durante 6 meses. Se recogieron datos demográficos (edad, sexo), antropométricos, glucemia basal, hemoglobina glicada (HbA1c), tensión arterial y perfil lipídico al inicio y a los 6 meses de tratamiento. Se ha realizado un análisis de regresión logística para evaluar posibles factores predictores de eficacia. Resultados: 30 pacientes (17 varones, edad media: 61,7±9,5 años) con DM-2 de 9,7±6,2 años de evolución. La HbA1c se redujo en 1,3% (IC95% 1,04-1,57, p. 
        </dc:description>
<dc:title xml:lang="en">[Effects of exenatide lar in type 2 diabetes mellitus and obesity].</dc:title>
<dc:publisher>Nutricion hospitalaria</dc:publisher>
</metadata>
</record>
</pubmed-document>
